medara

Overview

Medara is an artificial intelligence platform founded in January 2025 and headquartered in New York, NY[4][5]. The company uses artificial intelligence to analyze medical imaging and clinical data to predict cancer risk and provide personalized risk assessments[2]. Medara's platform integrates with existing PACS infrastructure and routine breast imaging workflows, displaying patient-specific risk scores at radiologist review[3][8]. The company's model was trained and validated on almost 1 million mammogram images gathered from international sites and provides one-, two-, three-, four-, and five-year risk assessments for future breast cancer[7]. Medara was founded with seed funding from the Jacobs Technion-Cornell Institute[4] and in August 2026 was awarded a National Cancer Institute Grant to advance AI-powered personalized breast cancer risk assessment[6]. The company's leadership team, headed by founder and CEO Dr. Kendra Batchelder, was expanded in January 2026[11]. Medara's partners and collaborators include Columbia University, Weill Cornell Medicine, Cornell University, and the National Science Foundation[9].

medara's timeline records "Jan 2025: medara, Inc. founded with seed funding from the Jacobs Technion-Cornell Institute for AI medical imaging research." [4]

medara's about page fact block lists "Founded 2025," "Headquartered New York, NY," "Focus Breast Cancer" and "Backed By Cornell Tech." [5]

medara's workflow runs in three steps: image sets are sent to PACS after acquisition, medara analyzes the patient's imaging and clinical data to generate a personalized risk assessment, then displays the patient-specific risk score at radiologist review and prioritizes cases for follow-up. [8]

Business address: 11 E Loop Rd, New York, New York, 10304. [12]

Funding history

medara was founded in January 2025 with seed funding from the Jacobs Technion-Cornell Institute, and in August 2026 announced it was "Awarded a National Cancer Institute Grant to Advance AI-Powered Personalized Breast Cancer Risk Assessment." [6]

Growth & traction

medara says its model was "Trained and validated on almost 1 million mammogram images" with "Data gathered from international sites," and "Provides a 1-, 2-, 3-, 4-, and 5-year risk of future breast cancer." [7]

In December 2025 Crain's New York Business recognized medara for leadership in health care technology, and in May 2026 the company presented at the Purpose Summit: AI for Community Resilience at Civic Hall in New York City. [10]

medara's founder and CEO is Dr. Kendra Batchelder, and the company says its leadership team was expanded in January 2026 with clinical, regulatory, business development and engineering expertise. [11]

Partnerships

medara's "Partners & Collaborators" section lists Columbia University, NIH SBIR, Weill Cornell Medicine, VentureWell, Cornell University, the Jacobs Technion-Cornell Institute, NSF I-Corps, the National Science Foundation, Lowenstein Sandler Venture Crush FGX and VentureWell Aspire. [9]